Pelthos Therapeutics is a biopharmaceutical company. Its lead product includes ZELSUVMI(TM) topical gel. Pelthos Therapeutics, formerly known as Channel Therapeutics Corporation, is based in DURHAM, N.C.
| Revenue (Most Recent Fiscal Year) | $16.80M |
| Net Income (Most Recent Fiscal Year) | $-43.32M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.70 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -301.91% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -141.43% |
| Return on Assets (Trailing 12 Months) | -47.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.05 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.15 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.81 |
| Inventory Turnover (Trailing 12 Months) | 0.33 |
| Book Value per Share (Most Recent Fiscal Quarter) | $12.02 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.83 |
| Earnings per Share (Most Recent Fiscal Year) | $-15.98 |
| Diluted Earnings per Share (Trailing 12 Months) | $-20.75 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 3.36M |
| Free Float | 2.93M |
| Market Capitalization | $68.45M |
| Average Volume (Last 20 Days) | 4413.35 |
| Beta (Past 60 Months) | 3.93 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.96% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |